Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
EyePoint Pharmaceuticals Inc (EYPT)
NASDAQ:EYPT
RESEARCH TOOLSreports
Holding EYPT?
Track your performance easily
Earnings Data
Report Date
Feb 27, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.5Last Year’s EPS
-$0.33Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 07, 2024
|% Change Since: -41.23%
|Next Earnings Date:Feb 27, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements in financial strength, strategic transformation, and positive clinical trial results. The main challenge noted was a decrease in net product revenue due to exiting the commercial business, but this was part of a strategic shift. Overall, the sentiment is positive as the company is well-capitalized and on track with its clinical and strategic goals.Company Guidance
During the EyePoint Pharmaceuticals Fourth Quarter and Full Year 2023 earnings call, the company provided detailed guidance on its clinical and financial outlook. EyePoint plans to start the pivotal Phase III Lugano trial for EYP-1901 in wet AMD in the second half of 2024, with a subsequent pivotal trial, the Lucia trial. The company anticipates reporting top-line data from the Phase II PAVIA trial in the second quarter of 2024 and from the Phase II VERONA trial in the first quarter of 2025. Financially, EyePoint ended 2023 with $331 million in cash and investments, expecting this to fund operations through the Phase III trials in 2026. Operating expenses for Q4 2023 decreased to $30.4 million, compared to $54.3 million in the prior year. The company also highlighted its strategic exit from the commercial business, which impacted net product revenue but was offset by an increase in royalties and collaborations revenue.Strong Financial Position
EyePoint Pharmaceuticals ended 2023 with $331 million in cash and investments and no debt, driven by the YUTIQ sale and a $230 million oversubscribed follow-on equity offering.
Positive Clinical Trial Results for EYP-1901
Phase II DAVIO 2 trial for EYP-1901 in wet AMD achieved all primary and secondary endpoints. No EYP-1901 related ocular or systemic serious adverse events reported.
Strategic Transformation
Completed transformation into a clinical stage biopharmaceutical company with the out-license of the YUTIQ franchise for $82.5 million plus future royalties.
Increased Revenue from Royalties
Net revenue from royalties and collaborations for Q4 2023 totaled $13.3 million, compared to $0.6 million in Q4 2022.
---
EYPT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
EYPT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $12.08 | $11.59 | -4.06% |
| Aug 07, 2024 | $9.02 | $8.65 | -4.10% |
| May 08, 2024 | $11.87 | $11.56 | -2.61% |
| Mar 07, 2024 | $25.74 | $25.31 | -1.67% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does EyePoint Pharmaceuticals Inc (EYPT) report earnings?
EyePoint Pharmaceuticals Inc (EYPT) is schdueled to report earning on Feb 27, 2025, TBA Not Confirmed.
What is EyePoint Pharmaceuticals Inc (EYPT) earnings time?
EyePoint Pharmaceuticals Inc (EYPT) earnings time is at Feb 27, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is EYPT EPS forecast?
EYPT EPS forecast for the fiscal quarter 2024 (Q4) is -$0.5.
---